Skip to main content
MedPathMedPath Home
Clinical Trials/NCT01455961
NCT01455961
Completed
N/A

An Epidemiological Registry Study to Evaluate Clinical Practice Treatment in Patients With Bipolar Disorder Treated With Quetiapine XR and/or Quetiapine IR

AstraZeneca0 sites16,000 target enrollmentNovember 2011
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsBipolar Disorder

Overview

Phase
N/A
Intervention
Not specified
Conditions
Bipolar Disorder
Sponsor
AstraZeneca
Enrollment
16000
Primary Endpoint
Description of detailed clinical treatment in terms of duration of treatment, doses, drug switches, and add-on therapy, in patients with BD and on treatment with quetiapine XR and/or quetiapine IR before, at and after the index date.
Status
Completed
Last Updated
11 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

The aim of this study is to describe the treatment pattern and patient characteristics in real life setting in patients with Bipolar disorder treated with Seroquel XR and/or Seroquel IR in Sweden.

Detailed Description

An epidemiological registry study to evaluate clinical practice treatment in patients with Bipolar Disorder treated with quetiapine XR and/or quetiapine IR

Registry
clinicaltrials.gov
Start Date
November 2011
End Date
April 2012
Last Updated
11 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • •Patients with a diagnosis of BD.

Exclusion Criteria

  • •Patients with a diagnosis of any schizophrenia spectrum disorder after the diagnosis of bipolar disorder.

Outcomes

Primary Outcomes

Description of detailed clinical treatment in terms of duration of treatment, doses, drug switches, and add-on therapy, in patients with BD and on treatment with quetiapine XR and/or quetiapine IR before, at and after the index date.

Time Frame: 1st of January 2009 to 31st of December 2010.

Secondary Outcomes

  • Description of co-morbidity, demographics, sick leave, early retirement and socioeconomic factors in patients with BD and on treatment with quetiapine XR and/or quetiapine IR before and at the index date.(1st of January 2009 to 31st of December 2010.)
  • Description of the detailed clinical treatment in terms of duration of treatment, doses, drug switches, and add-on therapy, in patients with BD, including all drug treatment after the index date(1st of January 2009 to 31st of December 2010.)
  • Description of co-morbidity, demographics, sick leave, early retirement and socioeconomic factors in patients with BD, including all drug treatment before and at the index date(1st of January 2009 to 31st of December 2010.)

Similar Trials

Completed
N/A
PROFILe3: Epidemiologic Survey in Patients With Schizophrenia or Schizoaffective DisordersSchizophreniaSchizoaffective DisorderSchizophreniform Disorder
NCT00399334Janssen-Cilag, S.A.1,607
Completed
N/A
A Disease Registry of Patients With Mantle Cell LymphomaMantle Cell Lymphoma
NCT03816683AstraZeneca227
Terminated
N/A
Demographics and Findings of Upper Endoscopy PatientsBarrett EsophagusGastroesophageal Reflux
NCT00576992Midwest Biomedical Research Foundation1,177
Completed
N/A
A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel.Metastatic Breast Cancer
NCT04671615Pfizer559
Recruiting
N/A
A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung CancerAdvanced Lung Cancer
NCT06183762Hunan Province Tumor Hospital200